Using a systems biology approach, the researchers discovered 64 genes shared between non-alcoholic fatty liver disease (NAFLD) and hypertension, considered to be core genes for the 2 conditions.
Researchers suggested non-alcoholic fatty liver disease (NAFLD) and hypertension could be considered a systemic disease after finding the 2 conditions have common disease pathogenic mechanisms.
Through a systems biology approach, the researchers discovered 64 genes shared between NAFLD and hypertension that were considered core genes for the 2 conditions. Among these genes was Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1), which was identified as a mediator for liver physiology and the interaction between NAFLD and hypertension. According to the researchers, this gene serves as a potential treatment target.
Notably, the group revealed treatments for cardiovascular diseases, hypertension, hyperlipidemia, inflammatory diseases, and depression could also be leveraged for concurrent hypertension and NAFLD.
The study findings follow previous research which indicated a higher prevalence of hypertension in patients with NAFLD or non-alcoholic steatohepatitis (NASH) compared with the general population (39.3% and 68% vs 29%, respectively). In one meta-analysis, data revealed an odds ratio of 1.24 for hypertension in patients with NAFLD when compared with the general population.
“According to another meta-analysis published in 2016, the comorbidity of NAFLD and hypertension was reported in the majority of the included studies, while the comorbidity of NASH and hypertension were reported in only 4 studies,” researchers wrote.
They continued, “the pooled overall prevalence of hypertension estimated in NAFLD and NASH patients was 39.34% and 67.97%. Another meta-analysis containing 411 biopsy-proven NAFLD patients reported an odds ratio of 1.94 (95% confidence interval 1.00 to 3.74) for liver progressive fibrosis in people with hypertension compared with those without hypertension.”
In the current analysis, researchers found over 20 studies that drew a connection between hypertension and NAFLD, indicating that hypertension may independently contribute to NAFLD or that NAFLD is a risk factor for hypertension.
According to authors, the evidence collected from the studies points to a link between blood pressure regulation and metabolic and histologic conditions in the liver, as well as a “potential reciprocal causation” of the 2 conditions.
“We identified that leukocytes had a strong association with NAFLD, NAFLD-related phenotypes and hypertension, which could be considered as an important immune cell type connecting hypertension and NAFLD,” commented the researchers. “Pathologically, the progression of NAFLD in steatohepatitis was characterized by hepatic leukocyte accumulation, which means that leukocytes were recruited from the blood and relocated at the liver tissue.”
Reference: Ma C, Yan K, Wang Z, et al. The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. Bioengineered. Published online June 6, 2021. doi:10.1080/21655979.2021.1933302
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
2 Clarke Drive
Cranbury, NJ 08512